Analysts’ Recent Ratings Changes for Fate Therapeutics (FATE)

Fate Therapeutics (NASDAQ: FATE) recently received a number of ratings updates from brokerages and research firms:

  • 1/19/2018 – Fate Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $8.00 price target on the stock. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. “
  • 1/18/2018 – Fate Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.
  • 1/16/2018 – Fate Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. “
  • 1/9/2018 – Fate Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.50 price target on the stock. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. “
  • 12/31/2017 – Fate Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 12/22/2017 – Fate Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 12/18/2017 – Fate Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
  • 12/18/2017 – Fate Therapeutics is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $10.00 price target on the stock.
  • 12/13/2017 – Fate Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
  • 12/12/2017 – Fate Therapeutics had its “buy” rating reaffirmed by analysts at Raymond James Financial, Inc..
  • 12/1/2017 – Fate Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.

Fate Therapeutics Inc (NASDAQ FATE) traded up $0.19 during trading on Monday, hitting $7.37. The company had a trading volume of 413,600 shares, compared to its average volume of 525,577. The stock has a market capitalization of $414.48, a P/E ratio of -7.76 and a beta of 1.52. Fate Therapeutics Inc has a 12-month low of $2.52 and a 12-month high of $7.40. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.95 million. Fate Therapeutics had a negative return on equity of 84.90% and a negative net margin of 1,041.33%. The firm’s revenue was up .0% compared to the same quarter last year. research analysts expect that Fate Therapeutics Inc will post -0.98 EPS for the current fiscal year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Receive News & Ratings for Fate Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply